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A B S T R A C T
Viral pneumonia is a prevalent cause of respiratory infection in immunocompetent adults. 
It has varied presentation, from mild to severe respiratory failure, requiring mechanical 
ventilation. However, in Brazil, there have been few studies on the clinical presentation 
and diagnosis of this infection. Thus, the authors of the present article intend to review the 
main viral agents that cause community-acquired pneumonia and to discuss the currently 
available diagnostic and therapeutic methods.
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Introduction
Pneumonia remains as one of the leading causes of worldwide 
morbidity and mortality1 and, in spite of recent advances in 
the field of diagnosis, it has been estimated that the causative 
infectious agent is accurately identified in less than 50% of 
cases.2 
In Brazil, the majority of studies on community-acquired 
pneumonia address mostly treatment options and clinical 
outcomes, and little is known about the local microbiological 
standards.2 
Bacteria remain as the main group of identified pathogens, 
but the actual role of other agents such as fungi, protozoa, and 
viruses is yet to be elucidated. 
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R E S U M O
A pneumonia de origem viral é uma causa prevalente de infecção respiratória em adultos 
imunocompetentes. Tem apresentação variada, ocasionando desde formas leves a quadros 
graves de insuficiência respiratória com necessidade de ventilação mecânica. Contudo, 
em nosso país, há poucos estudos a respeito da apresentação clínica e diagnóstico dessa 
infecção. Dessa forma, os autores do presente artigo têm por objetivo revisar os principais 
agentes virais causadores de pneumonia na comunidade e discutir as modalidades 
diagnósticas e terapêuticas disponíveis atualmente.
© 2013 Elsevier Editora Ltda. 
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Although viruses have been identified as an important 
cause of community-acquired pneumonia, only recently, 
mainly due to the 2009 pandemic, there has been a greater 
interest in the role of these agents.3 Among the main viruses 
that cause pneumonia in immunocompetent adults are the 
influenza virus, the respiratory syncytial virus (RSV), the 
adenovirus, and the human parainfluenza virus (HPIV). The use 
of new molecular techniques has allowed the identification of 
viruses that were seldom identified before, such as rhinovirus, 
metapneumovirus, and coronavirus.1,4
This review aims to demonstrate the modalities of 
complementary assessment and the currently available 
treatment options, and to discuss the main viruses implicated 
in the pathogenesis of community-acquired pneumonia in 
immunocompetent adults.  
Complementary diagnostic investigation
The incidence of viral pneumonia has increased significantly 
in recent years, and, depending on the agent virulence and 
patient comorbidities, its presentation may range from mild 
and self-limiting to extremely severe cases, with respiratory 
failure. The results of laboratory tests, clinical outcomes, and 
specific patterns identified on imaging studies, considered 
in the past as reliable identifiers of the infection etiology, 
are nonspecific, and their importance in diagnosis remains 
uncertain.5 Thus, the use of new complementary laboratory 
tests with higher sensitivity and specificity contributes to the 
definitive diagnosis, optimizing the treatment of this disease.3 
However, it should be noted that the isolation of these 
agents does not necessarily mean an active infection. In this 
context, it is essential to know the diagnostic options for 
identification of viruses, as well as the limitations of each 
method for adequate clinical interpretation.
The currently validated methods to define the etiology of 
viral infection, summarized in Table 1, are serology, culture, 
cytological evaluation, rapid detection of antigens, and gene 
amplification techniques, even though they are not widely 
available and are often costly.  
Serological analysis
Virtually all viruses can be diagnosed through serology. 
However, it is necessary to collect paired blood samples (acute/
convalescent phases), as a four-fold titer increase in relation 
to the first sampling is necessary to confirm the diagnosis. 
Therefore, serology is not routinely used, as it has been shown 
to be of little use in the acute phase of the disease, because 
titers rarely increase at this stage.4
In the study’s setting, serology is available for many of the 
community respiratory viruses such as adenovirus, RSV, and 
seasonal influenza. 
Cultures 
Viral culture can also be employed for most of the respiratory 
viruses, with the long time necessary to obtain the results 
being a disadvantage, as well as the need for specific culture 
mediums.4 
To perform the cultures, tissue samples from the upper 
and/or lower airways, sputum, and nasopharyngeal and 
bronchoalveolar lavage can be used.4 The cytopathic effects 
of the viruses are observed in cell cultures, such as the 
formation of syncytial collections of multinucleated giant 
cells, or evidence of viral growth. The subsequent identification 
of specific viruses in cell cultures may be accomplished by 
immunofluorescence techniques (direct or indirect), or nucleic 
acid probes.4 Other disadvantages of this method are high cost, 
low availability in clinical practice, and also the low yield for 
some specific agents such as RSV, human metapneumovirus, 
and coronavirus.4 
Cytological assessment 
This model can use samples from respiratory tissues and 
also secretions such as nasal and bronchoalveolar lavage. 
The technique aims at identifying nuclear (virus DNA) or 
cytoplasmic (virus RNA) inclusions, which are normally 
present in infected cells. The identification of the presence of 
such inclusions confirms the diagnosis.4
Table 1 – Options available for diagnostic investigation of the major pneumonia-causing viruses in the community. 
Virus Serology Culture Cytological assessment Rapid detection of antigens Gene amplification 
Influenza + HA/SV – IF/ELISA RT-PCR
RSV + CE/SV eosinophilic cytoplasmic inclusions IF/ELISA RT-PCR
Adenovirus + CE/SV intranuclear inclusions IF/ELISA RT-PCR
Parainfluenza - HA/SV eosinophilic cytoplasmic inclusions IF/ELISA RT-PCR
RSV, respiratory syncytial virus; IF, immunofluorescence; HA, hemagglutination; SV, shell viral culture; CE, cytopathogenic effects; ELISA, 
enzyme-linked immunosorbent assay; RT-PCR, reverse transcriptase polymerase chain reaction. 
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The disadvantage of this method is its low sensitivity, so that 
the absence of these findings cannot rule out active disease. 4
Rapid antigen detection
These are rapid tests performed  in easily obtainable 
specimens, such as nasal swab or wash. The enzyme-linked 
immunosorbent assay (ELISA) test is available for most 
pathogenic respiratory viruses; it is capable of detecting viral 
antigens, whereas the immunofluorescence requires intact 
infected cells. Both methods have varied sensitivity and 
specificity, depending on the agent analyzed. Specificity for 
seasonal influenza, for instance, is approximately 90% and 
sensitivity is 60%. However, when the suspected agent is the 
H5N1 influenza virus, the yield is extremely low, and therefore 
not recommended for confirmation of infection by this agent.4
The antigens remain positive for weeks, but are 
less sensitive than viral culture and can be used in a 
complementary way to increase the diagnostic yield of the 
sampled material.6
Gene amplification 
The polymerase chain reaction (PCR) or reverse transcriptase-
polymerase chain reaction (RT-PCR) techniques are 
extremely sensitive and specific to detect virus presence. 
It is the examination of choice for most respiratory viruses 
and, if available, should be employed together with the 
aforementioned diagnostic methods. The current development 
of this technique has allowed the knowledge of new causative 
agents of bronchiolitis and pneumonia in both pediatric and 
adult populations.7
This method can be applied to samples of nasopharyngeal 
or bronchial secretion swabs, and has the advantage that 
it can be performed in other body fluids such as blood 
of immunocompromised patients suspected of having 
cytomegalovirus infection.4
A new molecular technique called multiplex reverse 
transcriptase polymerase chain reaction (MRT-PCR) allows 
for the rapid detection of several respiratory viruses 
such as influenza A and B; RSV A and B; HPIV 1, 2, and 3; 
metapneumovirus; and adenovirus. Its disadvantage is the 
low sensitivity for H1N1 influenza, described by the method 
as nontypeable.8
Etiological agents, manifestations and treatment
Influenza
Influenza is an RNA virus of the Orthomyxoviridae family and 
three serotypes, A, B, and C, have been described. These viruses 
are responsible for approximately 4% to 8% of pneumonia 
cases in healthy adults, and higher rates were found during 
outbreaks and epidemics.9,10
Influenza A can be disseminated by aerosols and affect 
the entire respiratory tract. Commonly, it is the most virulent 
serotype, comprising a number of other subtypes. Influenza 
B usually causes disease in populations confined to closed 
spaces, such as daycare centers and boarding schools. 
Influenza C is the least common serotype, and is found as 
pathogenic agent in sporadic reports.10 
Influenza viruses A and B are responsible for approximately 
50% of community-acquired viral pneumonia in adults. Their 
impact is greater in the elderly and other at-risk populations 
such as pregnant women, immunocompromised patients, 
and patients with chronic diseases, especially heart and lung 
diseases.10
Recently, a subtype of influenza A, H1N1, known as the 
swine-flu agent, has emerged as an important and threatening 
pandemic, severely affecting immunosuppressed patients such 
as transplant recipients and other high-risk populations such 
as pregnant women, obese patients, and those with heart 
and lung disease. The affected individuals were generally 
younger than those affected by seasonal influenza.11,12 It has 
been estimated that there were approximately 16,226 deaths 
from April 2009 to January 2010 according to estimates by 
the World Health Organization. In Brazil, 10% to 30% of the 
admitted patients required admission to an intensive care unit, 
and of the total, 60% to 88% required mechanical ventilation. 
The mortality rate for H1N1 in the country was 70 deaths per 
100,000 inhabitants.12,13
Infection by the influenza virus leads to cell death, 
especially in the upper airways. When the virus infects 
the lower airways directly, there may be bleeding without 
proportional accumulation of inflammatory cells. There is 
also mucociliary clearance impairment, which may determine 
bacterial adherence to the respiratory epithelium. Impaired 
function of T-cells, macrophages, and neutrophils also occurs, 
which leads to decreased host defenses. All these events 
together facilitate the frequently observed concomitant 
bacterial infection.14
The incubation period is one to two days and symptoms 
typically last three to five days. There are three clinical 
presentations: primary influenza pneumonia, influenza 
infection with secondary bacterial pneumonia, and 
simultaneous coinfection (viral and bacterial).14
Primary pneumonia manifests as persistent cough, 
pain in the throat, headache and myalgia for over five 
days, associated with the onset of progressive dyspnea 
and cyanosis. This is the less common, albeit more severe, 
presentation. Influenza pneumonia with secondary bacterial 
infection is characterized by intensification of high fever, 
cough, and purulent sputum after initial improvement, 
associated with the appearance of new opacities on chest 
radiography. The main agents involved are Streptococcus 
pneumoniae (48%), Staphylococcus aureus, and Haemophilus 
influenzae .  Pneumonia caused by viral and bacterial 
coinfection manifests similarly to pneumonia with secondary 
bacterial infection, but there is no initial improvement. 
In this context, both the virus and the bacterial agent are 
isolated together in the microbiological analysis.14
Inflammatory markers such as C-reactive protein and 
procalcitonin are also of little use when differentiating 
between bacterial and viral pneumonia, as the most severe 
cases, as observed in the H1N1 pandemic, showed high levels 
of these two substances in patients with viral pneumonia.15
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Fig. 1 - Coronal (A) and axial (B) views of chest CT scan in 
a patient with pneumonia caused by seasonal influenza A 
virus, showing diffusely distributed ground-glass opacities. 
The pulmonary and radiological alterations are nonspecific 
and can be seen as perihilar and peribronchial opacities, 
consolidations, and diffuse bilateral interstitial opacities, 
especially in more severe forms of the disease or in 
neutropenic patients (Fig. 1).16
The influenza virus can be isolated in sputum, nasal lavage, 
or nasal and pharyngeal swabs, with lower yield for the latter 
in culture medium. 90% of the positive cultures are detected 
within three days of inoculation and the remainder up to the 
seventh day. Rapid tests have high specificity for influenza 
Amantadine and rimantadine have been approved for 
prevention and treatment, and are not effective against 
influenza B. They work by blocking the ion channels of the 
viral M2 protein and inhibit its decapsulation. Its use should be 
indicated within 48 hours of symptom onset in uncomplicated 
cases, but its effectiveness has not been tested in severe 
pneumonia. Furthermore, many strains are now resistant 
to these drugs, thus they should not be recommended as an 
empirical single-drug therapy.3
Oseltamivir and zanamivir are drugs that block the surface 
protein neuraminidase and trap the virus within the infected 
respiratory epithelium, preventing its dissemination. They too 
should be preferably administered within 48 hours of symptom 
onset. They are active against influenza A and B, and have low 
potential to induce resistance, although some cases have been 
described in the United States during the H1N1 pandemic. In 
cases of severe pneumonia, medication can be provided even 
after 48 hours of symptom onset.18 
When there is potentially fatal respiratory failure, as in 
many cases of the H1N1 pandemic, rescue maneuvers for 
refractory hypoxemia, such as recruitment and ventilation 
in the prone position, may be instituted in combination with 
antiviral therapy.19
Respiratory syncytial virus 
RSV is part of the Paramyviridae family, and is the most 
common cause of lower respiratory infection in children.20 
It has currently been identified as an important cause of 
pneumonia in adults, especially in the elderly, and has become 
the second most frequent cause among the viruses found in 
this population. RSV is highly contagious, spreading through 
droplets and fomites. The population at risk consists mainly 
of children younger than six months; patients with chronic 
diseases, such as cystic fibrosis; patients with congenital 
heart disease; institutionalized elderly individuals; and 
immunosuppressed patients.21 The overall mortality in adults 
varies according to the immune status, from 1% to 5% in 
healthy adults to 41% in bone marrow transplant recipients.22 
Table 2 – Main drugs used to treat the principal viruses that cause community-acquired pneumonia
Action mechanism Drugs Posology Virus
Neuraminidase Inhibitors Oseltamivir
 
Zanamivir
75-150 mg twice a day
 for five days (oral route)
10 mg twice a day for five days (aerosol)
Influenza A and B
M2 protein inhibitors Amantadine
Rimantadine
100 mg twice a day for five days (oral route)
200 mg once a day for five days (oral route)
Influenza A
Unknown Ribavirin (20 mg/mL) 18 hrs/day (aerosol) for three to six days with a 
nebulizer
RSV
Adenovirusa
Parainfluenza
RSV, respiratory syncytial virus. 
aFor adenovirus, consider the association with cidofovir (5 mg/Kg – once a week, IV route).
viruses A and B (85% to 100%), but low sensitivity (40% to 80%).
It is noteworthy that in suspected H5N1 cases, this test 
is not recommended, as the RT-PCR analysis has greater 
diagnostic usefulness. Histological assessment is another 
possible diagnostic option, achieved by ultrastructural analysis 
through lung biopsy.17
The treatment must be performed with supportive measures 
such as supplemental oxygen, analgesics, antipyretics, and 
antiviral therapy in selected cases. The drugs approved for the 
treatment of influenza infection are amantadine, rimantadine, 
oseltamivir, and zanamivir (Table 2).17
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RSV is rarely diagnosed in adults. The infection is 
characterized by persistent symptoms in the upper airways, 
such as runny nose, earache, and sore throat, associated with 
prolonged cough (whether dry or productive), dyspnea, and 
wheezing; it may cause bronchitis, bronchiolitis, and severe 
pneumonia requiring mechanical ventilation. Compared to the 
influenza virus infection, a higher frequency of rhinorrhea and 
purulent sputum is observed, as well as a lower frequency of 
fever and gastrointestinal symptoms.23 
Some inflammatory markers obtained from airways and blood, 
such as soluble intercellular adhesion molecule type I (sICAM-1), 
interleukin 10 (IL-10), and IL-6 were tested in children and appear 
to show a positive correlation, at higher concentrations, with the 
severity and duration of hospitalization.24 
The pulmonary radiological findings associated with RSV 
infection are nonspecific; bilateral alveolar opacities and 
interstitial alterations are described in most cases, similar to 
those observed in influenza virus infection.21,22
The virus can be isolated in culture, where the highest yield 
is found in samples of nasopharyngeal lavage and tracheal 
secretions. In immunosuppressed patients, a positive culture is 
found in up to 15% of nasopharyngeal lavage samples, in up to 
71% of tracheal secretions, and in up to 89% of bronchoalveolar 
lavage. Rapid tests for detection of viral antigens have a 
sensitivity of 50% to 90% and a high specificity (90%-95%). Gene 
amplification with RT-PCR is also available.23
Ribavirin works by preventing viral transcription and is 
the only currently available antiviral drug for the treatment 
of RSV pneumonia (Table 2). The current recommendation is 
that the medication should only considered for severe cases 
or in patients at high risk of complications. Intravenous 
immunoglobulin specific for RSV (palivizumab) can also be 
used in combination with ribavirin in critically-ill patients and 
those at high risk for complications, especially in bone marrow 
transplant recipients.24 
Adenovirus
Adenovirus is a highly contagious DNA virus, and there are 52 
different serotypes. Adenovirus infection can occur at any time 
of the year, accounting for approximately 10% of pneumonias 
in children. Historically, this virus is also identified as an 
important causative agent of respiratory infection outbreaks 
in military bases in the United States.25  
Its serotypes are classified into seven subgroups or species 
(A to G), and pulmonary infections are caused predominantly 
by serotypes 1, 2, 3, 4, 5, 7, 14, and 21. Although it is a virus 
that determines low mortality, subtype 14 can cause severe 
respiratory failure in susceptible patients, such as solid-organ 
transplant recipients, individuals with HIV infection, and 
patients with other types of impaired cell immunity, although 
there are reports of fatal cases in the postoperative period after 
cardiac surgery in previously immunocompetent patients.26 
Adenovirus dissemination occurs by direct inoculation into the 
conjunctiva, aerosol, feces, and fomites; the virus is capable of 
surviving in contaminated areas of the environment for several 
weeks. Viral reactivation can also occur in immunosuppressed 
patients, resulting in several clinical syndromes, including 
keratoconjunctivitis, gastroenteritis, hepatitis, and 
hemorrhagic cystitis, associated or not with pneumonia. 
Pneumonia mortality rates range from 38% to 100%, especially 
in bone marrow transplant recipients.27   
The clinical picture is characterized by fever, cough, runny 
nose, sore throat, tonsillitis, and otitis media, with a mean 
duration of three to five days. Leukocytosis and elevated 
inflammatory activity can be observed, and it is important to 
differentiate from bacterial infections. Pulmonary opacities are 
often reticulonodular in radiological images, but consolidations 
can also be observed.27,28 
Respiratory secretion cultures can be performed to confirm 
the diagnosis, which can be demonstrated by cytopathic effects 
two to 20 days after onset. Serotype 14 can be diagnosed by 
rapid antigen detection and PCR techniques, especially in 
immunosuppressed patients.27,28
There are no controlled studies regarding the best treatment 
option, or which drug is more adequate for each specific clinical 
syndrome. Thus, the use of antivirals is based on recommendation 
from experts and case reports. The drugs that can be used are 
ribavirin, cidofovir, ganciclovir, and vidarabine, with a larger 
number of reports favoring the combined therapy with cidofovir/
ribavirin, especially in patients with a history of unfavorable 
evolution and bone marrow transplantation (Table 2).28
Human parainfluenza virus
HPIV is a paramyxovirus classified into four subtypes (1, 2, 3, 
and 4). This virus is the second most common cause of viral 
infection in children, accounting for approximately 30% to 40% 
of respiratory infections; it is also identified as a causative 
agent of pneumonia in adults (mainly HPIV serotypes 1 and 
3). Transmission can occur through direct contact with the 
infected host, by respiratory droplets, or by fomites.29
Once installed, the infection causes the secretion of high 
levels of inflammatory cytokines such as interferon alpha, 
IL-2, IL-6, and tumor necrosis factor alpha (TNF-alpha). These 
mediators are responsible for the abundant production of 
mucus in the respiratory epithelium, submucosal edema, and 
vocal cords, which can determine the partial obstruction of the 
upper airway and the characteristic stridor of this disease.29
The incubation period lasts one to three days and the 
characteristic symptoms of croup, such as hoarseness and 
stridor (steeple sign), common in children, are less prevalent 
in immunocompetent adults. HPIV-3 is the primary strain 
causing bronchiolitis and pneumonia, leading to the onset of 
nonspecific symptoms such as fever, runny nose, wheezing, 
dry cough, and dyspnea. The symptoms can mimic a number of 
other respiratory infections, especially in immunosuppressed 
individuals; the identification of marked upper airway 
involvement, such as sinusitis and stridor, is an important 
clue for diagnosis. Reports of bronchiolitis obliterans with 
organizing pneumonia and giant-cell pneumonia have also 
been described after infection by this agent.29
From the radiological point of view, the alterations often 
observed are the focal alveolar opacities, although a diffuse 
interstitial pattern has also been described. A previous study 
showed that infection may be associated with the presence 
of multiple noncavitated nodules < 5 mm with peribronchial 
distribution.29,30 
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Isolation by culture can be carried out preferably in nasal 
secretions. RT-PCR is the faster and most sensitive diagnostic 
method.29,30
Supportive care is usually enough, and specific therapy 
should be recommended only for patients at high risk or with 
severe symptoms. In these cases, the agent of choice, based on 
in vitro study and a case study, is oral or aerosolized ribavirin 
(Table 2).31
Other agents
With the advancement of diagnostic methods and greater 
access to PCR, other agents such as metapneumovirus, 
rhinovirus, and coronavirus have been currently recognized 
as causing community-acquired pneumonia.32
The human metapneumovirus is a relatively new virus as 
a respiratory pathogen, and was initially described in 2001 
in the Netherlands. This virus belongs to the same family 
as RSV and HPIV, is usually acquired in early childhood, and 
causes bronchiolitis, croup, and pneumonia. Reinfection can 
occur in adulthood, with the most severe cases affecting 
the elderly, individuals with heart and lung disease, and 
immunocompromised patients. The incubation period is 
approximately five days; the clinical picture is similar to that 
of other viruses, with nasal congestion, coughing, wheezing, 
fever, and dyspnea. Hoarseness is the most common finding 
in RSV infection. Chest images show bilateral alveolar 
opacities in 43% of cases, and nodular opacities and pleural 
effusion can also occur. It is a difficult virus to isolate in 
cultures, with extremely slow replication rates. RT-PCR is 
the method of choice for the diagnosis.33 The treatment is 
yet to be well established, but the use of ribavirin alone or in 
combination with immunoglobulin appears to be promising 
in more severe cases.34 
Coronaviruses have been recognized as causing pneumonia 
after a serious epidemic in China during 2003. Four human 
subtypes have been recognized: HCoV-229E, HCoV-OC43, 
HCoV-NL63, and HCoV-HKU1. The incubation period of 
coronavirus-associated infection is of two to five days; the 
most common symptoms are myalgia, chills, and dyspnea, 
with possible progression to respiratory failure, while fever 
is uncommon. Other findings that may be observed are 
thrombocytopenia, elevated levels of transaminases, and 
D-dimer. The radiological pattern is nonspecific, commonly 
demonstrating diffuse pulmonary ground-glass opacities 
on chest tomography. Cases of pneumomediastinum have 
also been reported.35,36 In cases of severe outcome, protease 
inhibitors, such as lopinavir and ritonavir, and interferon-
alpha and -beta can be administered. There is no evidence of 
efficacy for ribavirin use.37 
The Rhinovirus, a member of the Picornaviridae family, is 
the major cause of colds in the general population, and it is 
the second most prevalent agent as the cause of bronchiolitis 
in the pediatric population - in some studies, it has been 
shown to be the agent more often related to exacerbations 
in asthmatic children.38 Although controversial, some studies 
have shown a prevalence of this virus in up to 30% of cases 
of severe pneumonia hospitalized in intensive care.39 The 
diagnosis is difficult; it is attained through PCR techniques, 
as other methods (such as serological tests and cultures) 
are not feasible, and the rapid detection of antigens is not 
standardized.40 
Final considerations
As observed in the most recently published studies, 
viruses have been increasingly considered as the cause 
of serious respiratory infections or co-infections, even in 
immunocompetent patients. In this context, it is essential to 
consider the presence of these pathogens as potential causes 
of lung disease, and to increase the capacity to identify them. 
Together with the greater possibility of diagnosing viral 
infections, it will be feasible not only to increase the knowledge 
on epidemiological profile of viral community-acquired 
pneumonia, but also to plan better therapeutic and prevention 
strategies for society. 
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